Motilal Oswal's research report on Global Health
Global Health (Medanta) delivered better-than-expected revenue (9% beat) in 2QFY26. However, it delivered marginally lower-than-expected EBITDA/PAT (3%/2% miss) for the quarter. In-patient (IP) and out-patient (OP) volumes saw healthy mid-teen YoY growth for the fourth consecutive quarter. Realization per patient (ARPOB) increased due to the rising share of Oncology in case mix and better realization in other therapies.
Outlook
We trim our earnings estimates by 6%/2%/3% for FY26/FY27/FY28, factoring in additional costs from operations at Noida/Ranchi hospitals and a moderation in the profitability of matured hospitals. We value Medanta at 30x 12M forward EV/EBITDA to arrive at a TP of INR1,480.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
